Table 4.
Percentages of subjects with adverse events that were new or worsened since study entry (percentage ≥5% and percentage with atomoxetine ≥ percentage with placebo)
| Adverse event | Placebo % | Moxifloxacin % | Atomoxetine % |
|---|---|---|---|
| Application site reaction | 48.1 | 19.1 | 51.1 |
| Postural orthostatic tachycardia syndrome | 3.8 | 3.1 | 23.7 |
| Testicular pain | 3.1 | 0.8 | 13.0 |
| Blood pressure increased | 9.2 | 3.8 | 12.2 |
| Nausea | 2.3 | 1.5 | 10.7 |
| Erectile dysfunction | 2.3 | 0.8 | 10.7 |
| Urinary hesitation | 1.5 | 0.0 | 10.7 |
| Dyspepsia | 3.1 | 1.5 | 9.9 |
| Dry mouth | 2.3 | 0.0 | 9.9 |
| Anorexia | 0.0 | 0.0 | 9.1 |
| Dizziness | 1.5 | 1.5 | 6.1 |
| Nasopharyngitis | 4.6 | 0.8 | 6.1 |
| Insomnia | 2.3 | 0.0 | 6.1 |
| Dysuria | 1.5 | 0.0 | 5.3 |
| Sinus tachycardia | 0.0 | 0.0 | 5.3 |